Zobrazeno 1 - 10
of 17
pro vyhledávání: '"G J, Vosika"'
Publikováno v:
Molecular biotherapy. 2(1)
A new lipophilic immunomodulator, disaccharide tripeptide glycerol dipalmitoyl (DTP-GDP), has been synthesized and evaluated for its immunologic activity and toxicology. DTP-GDP alone or in liposomes is more effective as an adjuvant and in activating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1c9b56efe230054a625bee03ddb5126c
https://pubmed.ncbi.nlm.nih.gov/2185794
https://pubmed.ncbi.nlm.nih.gov/2185794
Publikováno v:
Cancer. 44(2)
The clinical efficacy of intralesional immunotherapy utilizing Mycobacterium smegmatis cell wall skeleton (CWS) and trehalose dimycolate attached to oil droplets was investigated in 15 patients with advanced malignant melanoma. Patients received 300
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::82733caad4710cbc460117c32315e775
https://pubmed.ncbi.nlm.nih.gov/476567
https://pubmed.ncbi.nlm.nih.gov/476567
Autor:
G J, Vosika, K, Briscoe, R W, Carey, J F, O'Donnell, M C, Perry, D, Budman, F, Richards, M, Coleman
Publikováno v:
Cancer treatment reports. 65(9-10)
A phase II study of diglycoaldehyde was conducted in 42 patients with malignant melanoma and soft tissue sarcoma. All patients received diglycoaldehyde at a dose of 2 g/m2 iv over 6 hours daily for 3 days. This was repeated every 28 days. Major toxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9c9b7439ce59cec55c6485a5054474f4
https://pubmed.ncbi.nlm.nih.gov/7273013
https://pubmed.ncbi.nlm.nih.gov/7273013
Autor:
D F, Chiuten, G J, Vosika, M T, Shaw, M, Boiron, C, Gisselbrecht, M, Marty, G, Higgins, F M, Muggia
Publikováno v:
Anticancer research. 1(2)
All Phase II studies with diglycoaldehyde with leukemia and solid tumors have been reviewed. The dose schedules employed ranged from 1.5 to 2.0 g/m2/day for 3 to 5 days. The most common side effects have been gastrointestinal (nausea and vomiting), w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e748551c55843d631b6f86a7ccdecb51
https://pubmed.ncbi.nlm.nih.gov/7347155
https://pubmed.ncbi.nlm.nih.gov/7347155
Publikováno v:
Cancer. 45(6)
The effectiveness of hypophysectomy and tamoxifen in treating advanced breast cancer was compared in a randomized study of 26 patients who had responded to prior oophorectomy or additive hormonal therapy. When patients failed to respond or relapsed f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::747fb02628fda93fbf21e3ae19df4051
https://pubmed.ncbi.nlm.nih.gov/6986976
https://pubmed.ncbi.nlm.nih.gov/6986976
Autor:
G J, Vosika, G R, Gray
Publikováno v:
Cancer treatment reports. 67(9)
A phase I study to determine the toxicity and immunologic effects of iv administered aqueous suspensions of mycobacterial cell wall skeleton (CWS) and CWS combined with trehalose dimycolate (TDM) was performed. A total of 26 patients received suspens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f91f29122d41d4ee5d1ddbfe442d19d2
https://pubmed.ncbi.nlm.nih.gov/6883355
https://pubmed.ncbi.nlm.nih.gov/6883355
Autor:
G J, Vosika
Publikováno v:
Minnesota medicine. 62(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::88d16dcf10b663557046765695b64664
https://pubmed.ncbi.nlm.nih.gov/386072
https://pubmed.ncbi.nlm.nih.gov/386072
Autor:
N J, Vogelzang, R C, Trowbridge, D H, Frenning, A, Theologides, B J, Kennedy, D R, Kelly, S L, Ewing, G J, Vosika
Publikováno v:
Cancer treatment reports. 64(8-9)
Forty consecutive patients with small cell bronchogenic carcinoma were treated. The first 18 patients were treated with CCNU and doxorubicin (Adriamycin) (CA). The next 22 patients were treated with CCNU, doxorubicin, procarbazine, and vincristine (C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5492ce75b7a378d8737cad0c4793255f
https://pubmed.ncbi.nlm.nih.gov/6256076
https://pubmed.ncbi.nlm.nih.gov/6256076
Publikováno v:
American journal of clinical oncology. 5(1)
Twenty-seven patients with advanced bronchogenic carcinoma were treated with vindesine, 3 mg/m2/week. Twenty-three patients were evaluable for response. Two of six patients with small-cell carcinoma and one of 17 patients with non-small-cell carcinom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e5c9f93217575914c1b45a1b57b86e14
https://pubmed.ncbi.nlm.nih.gov/6282107
https://pubmed.ncbi.nlm.nih.gov/6282107
Publikováno v:
American journal of clinical oncology. 6(5)
Sixteen patients, 13 of whom had received prior chemotherapy, were treated with vindesine for advanced malignant melanoma. Previous treatment included vinca alkaloids in six. Thirteen patients received vindesine, 4 mg/m2 and three received vindesine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::628332e23e6cf64946c383abd7b02533
https://pubmed.ncbi.nlm.nih.gov/6613921
https://pubmed.ncbi.nlm.nih.gov/6613921